Understanding the role of genetic variability in LRRK2 in Indian population.


Journal

Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688

Informations de publication

Date de publication:
04 2019
Historique:
received: 12 07 2018
accepted: 24 09 2018
pubmed: 30 11 2018
medline: 10 1 2020
entrez: 29 11 2018
Statut: ppublish

Résumé

Genetic variability in LRRK2 has been unequivocally established as a major risk factor for familial and sporadic forms of PD in ethnically diverse populations. To resolve the role of LRRK2 in the Indian population. We performed targeted resequencing of the LRRK2 locus in 288 cases and 298 controls and resolved the haplotypic structure of LRRK2 in a combined cohort of 800 cases and 402 controls in the Indian population. We assessed the frequency of novel missense variants in the white and East Asian population by leveraging exome sequencing and densely genotype data, respectively. We did computational modeling and biochemical approach to infer the potential role of novel variants impacting the LRRK2 protein function. Finally, we assessed the phosphorylation activity of identified novel coding variants in the LRRK2 gene. We identified four novel missense variants with frequency ranging from 0.0008% to 0.002% specific for the Indian population, encompassing armadillo and kinase domains of the LRRK2 protein. A common genetic variability within LRRK2 may contribute to increased risk, but it was nonsignificant after correcting for multiple testing, because of small cohort size. The computational modeling showed destabilizing effect on the LRRK2 function. In comparison to the wild-type, the kinase domain variant showed 4-fold increase in the kinase activity. Our study, for the first time, identified novel missense variants for LRRK2, specific for the Indian population, and showed that a novel missense variant in the kinase domain modifies kinase activity in vitro. © 2018 International Parkinson and Movement Disorder Society.

Sections du résumé

BACKGROUND
Genetic variability in LRRK2 has been unequivocally established as a major risk factor for familial and sporadic forms of PD in ethnically diverse populations.
OBJECTIVES
To resolve the role of LRRK2 in the Indian population.
METHODS
We performed targeted resequencing of the LRRK2 locus in 288 cases and 298 controls and resolved the haplotypic structure of LRRK2 in a combined cohort of 800 cases and 402 controls in the Indian population. We assessed the frequency of novel missense variants in the white and East Asian population by leveraging exome sequencing and densely genotype data, respectively. We did computational modeling and biochemical approach to infer the potential role of novel variants impacting the LRRK2 protein function. Finally, we assessed the phosphorylation activity of identified novel coding variants in the LRRK2 gene.
RESULTS
We identified four novel missense variants with frequency ranging from 0.0008% to 0.002% specific for the Indian population, encompassing armadillo and kinase domains of the LRRK2 protein. A common genetic variability within LRRK2 may contribute to increased risk, but it was nonsignificant after correcting for multiple testing, because of small cohort size. The computational modeling showed destabilizing effect on the LRRK2 function. In comparison to the wild-type, the kinase domain variant showed 4-fold increase in the kinase activity.
CONCLUSIONS
Our study, for the first time, identified novel missense variants for LRRK2, specific for the Indian population, and showed that a novel missense variant in the kinase domain modifies kinase activity in vitro. © 2018 International Parkinson and Movement Disorder Society.

Identifiants

pubmed: 30485545
doi: 10.1002/mds.27558
pmc: PMC8985845
mid: NIHMS1789438
doi:

Substances chimiques

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

496-505

Subventions

Organisme : PEARL programme
ID : FNR; FNR/P13/6682797
Pays : International
Organisme : German Research Council
ID : DFG; KR2119/8-1
Pays : International
Organisme : Intramural NIH HHS
ID : Z99 AG999999
Pays : United States
Organisme : Multiple System Atrophy Coalition, USA
Pays : International
Organisme : Luxembourg National Research Fund
Pays : International
Organisme : European Union's Horizon2020 research and innovation program
ID : 692320
Pays : International
Organisme : German Research Council
ID : DFG/SH 599/6-1
Pays : International
Organisme : National Centre of Excellence in Research on Parkinson's disease
Pays : International
Organisme : EU Joint Program-Neurodegenerative diseases
Pays : International
Organisme : Michael J Fox Foundation
Pays : International

Informations de copyright

© 2018 International Parkinson and Movement Disorder Society.

Références

Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Hum Mutat. 2009 Aug;30(8):1153-60
pubmed: 19472409
Parkinsonism Relat Disord. 2015 Oct;21(10):1170-6
pubmed: 26306001
Mol Cell Biol. 2006 May;26(9):3378-89
pubmed: 16611982
Front Genet. 2012 Mar 15;3:35
pubmed: 22435069
Sci Rep. 2018 Feb 22;8(1):3455
pubmed: 29472595
PLoS One. 2013 Sep 05;8(9):e75041
pubmed: 24040382
Neurosci Lett. 2006 Dec 1;409(2):83-8
pubmed: 17052850
FEBS J. 2009 Nov;276(22):6428-35
pubmed: 19804416
Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):E4357-66
pubmed: 27357661
Lancet. 2011 Feb 19;377(9766):641-9
pubmed: 21292315
Neurol India. 2013 Sep-Oct;61(5):457-66
pubmed: 24262445
Parkinsonism Relat Disord. 2008;14(1):77-80
pubmed: 17433753
Genet Test Mol Biomarkers. 2010 Oct;14(5):691-4
pubmed: 20722494
Eur J Hum Genet. 2006 Mar;14(3):322-31
pubmed: 16333314
Parkinsonism Relat Disord. 2012 Jul;18(6):801-2
pubmed: 22436655
Neurosci Lett. 2005 Aug 26;384(3):327-9
pubmed: 15955629
Nature. 2010 Sep 2;467(7311):52-8
pubmed: 20811451
Curr Top Med Chem. 2015;15(10):927-38
pubmed: 25832719
Neurol Sci. 2014 Oct;35(10):1495-504
pubmed: 25027012
Mov Disord. 2013 Oct;28(12):1740-4
pubmed: 23913756
Front Mol Neurosci. 2018 Feb 28;11:64
pubmed: 29541021
Neurobiol Aging. 2017 Sep;57:247.e9-247.e13
pubmed: 28602509
Proteomics. 2007 Dec;7(23):4228-34
pubmed: 17979178
Neurol India. 2011 Mar-Apr;59(2):157-60
pubmed: 21483109
Elife. 2016 Jan 29;5:
pubmed: 26824392
Bioinformatics. 2014 Sep 1;30(17):2503-5
pubmed: 24812344
Neurobiol Aging. 2015 Mar;36(3):1605.e7-12
pubmed: 25444595
Hum Genet. 2007 Feb;120(6):857-63
pubmed: 17019612
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
pubmed: 1564476
Hum Mol Genet. 2005 Dec 1;14(23):3549-56
pubmed: 16269443
Hum Mol Genet. 2006 Jan 15;15(2):223-32
pubmed: 16321986
Hum Mol Genet. 2007 Jun 1;16(11):1319-26
pubmed: 17409193
J Proteome Res. 2010 Apr 5;9(4):1738-45
pubmed: 20108944
Neurosci Lett. 2007 Apr 24;417(1):21-3
pubmed: 17395370
J Neurol Neurosurg Psychiatry. 2005 Nov;76(11):1588-90
pubmed: 16227559
Hum Genet. 2008 Oct;124(3):287-8
pubmed: 18781329
Lancet Neurol. 2008 Jul;7(7):583-90
pubmed: 18539534
Nat Genet. 2017 Oct;49(10):1511-1516
pubmed: 28892059
Nat Genet. 2014 Sep;46(9):989-93
pubmed: 25064009
Am J Hum Genet. 2007 Sep;81(3):559-75
pubmed: 17701901
Parkinsonism Relat Disord. 2014 Sep;20(9):1018-21
pubmed: 24997548
Trends Biochem Sci. 2011 Feb;36(2):65-77
pubmed: 20971646
Lancet Neurol. 2015 Jul;14(7):678-9
pubmed: 26067110
Hum Mol Genet. 2014 Jul 15;23(14):3891-7
pubmed: 24565865
Mov Disord. 2009 May 15;24(7):1034-41
pubmed: 19343804
Biomed Res Int. 2014;2014:867321
pubmed: 25243190
Lancet Neurol. 2011 Oct;10(10):898-908
pubmed: 21885347
Proteins. 2011 Mar;79(3):830-8
pubmed: 21287615
Bioinformatics. 2014 Oct;30(19):2813-5
pubmed: 24907369
Neurology. 2016 Mar 15;86(11):994-9
pubmed: 26865512
Ann Neurol. 2005 Nov;58(5):784-7
pubmed: 16240353
Genome Biol. 2017 Jan 30;18(1):22
pubmed: 28137300
Mov Disord. 2012 Dec;27(14):1822-5
pubmed: 23115130
Biochem J. 2016 Sep 1;473(17):2671-85
pubmed: 27474410
Neurobiol Aging. 2018 Apr;64:159.e5-159.e8
pubmed: 29398121

Auteurs

Asha Kishore (A)

Sree Chitra Tirunal Institute for Medical Science and Technology, Kerala, India.

Ashwin Ashok Kumar Sreelatha (A)

Centre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany.

Marc Sturm (M)

Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.

Felix von-Zweydorf (F)

German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Institute for Ophthalmic Research, Center for Ophthalmology, University of Tübingen, Tübingen, Germany.

Lasse Pihlstrøm (L)

Department of Neurology, Oslo University Hospital, Oslo, Norway.

Francesco Raimondi (F)

Cell Networks, University of Heidelberg, Heidelberg, Germany.

Rob Russell (R)

Cell Networks, University of Heidelberg, Heidelberg, Germany.

Peter Lichtner (P)

Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany.

Moinak Banerjee (M)

Rajiv Gandhi Centre for Biotechnology, Kerala, India.

Syam Krishnan (S)

Sree Chitra Tirunal Institute for Medical Science and Technology, Kerala, India.

Roopa Rajan (R)

Sree Chitra Tirunal Institute for Medical Science and Technology, Kerala, India.
All India Institute for Medical Sciences, New Delhi, India.

Divya Kalikavil Puthenveedu (DK)

Sree Chitra Tirunal Institute for Medical Science and Technology, Kerala, India.

Sun Ju Chung (SJ)

Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Peter Bauer (P)

Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.

Olaf Riess (O)

Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.

Christian Johannes Gloeckner (CJ)

German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Institute for Ophthalmic Research, Center for Ophthalmology, University of Tübingen, Tübingen, Germany.

Rejko Kruger (R)

Center of Neurology, and Hertie Institute for Clinical Brain Research, University Hospital, Tübingen, Germany.
LCSB, Luxembourg Centre for Systems Biology, University of Luxembourg, and Centre Hospitalier de Luxembourg (CHL), Luxembourg.

Thomas Gasser (T)

Center of Neurology, and Hertie Institute for Clinical Brain Research, University Hospital, Tübingen, Germany.

Manu Sharma (M)

Centre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH